IL297780A - Controlled modification of adeno-associated virus (aav) for enhanced gene therapy - Google Patents

Controlled modification of adeno-associated virus (aav) for enhanced gene therapy

Info

Publication number
IL297780A
IL297780A IL297780A IL29778022A IL297780A IL 297780 A IL297780 A IL 297780A IL 297780 A IL297780 A IL 297780A IL 29778022 A IL29778022 A IL 29778022A IL 297780 A IL297780 A IL 297780A
Authority
IL
Israel
Prior art keywords
aav
amino acid
genetically
modified
variant
Prior art date
Application number
IL297780A
Other languages
English (en)
Hebrew (he)
Original Assignee
Trustees Boston College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Boston College filed Critical Trustees Boston College
Publication of IL297780A publication Critical patent/IL297780A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL297780A 2020-05-01 2021-05-03 Controlled modification of adeno-associated virus (aav) for enhanced gene therapy IL297780A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018573P 2020-05-01 2020-05-01
PCT/US2021/030489 WO2021222899A1 (en) 2020-05-01 2021-05-03 Controlled modification of adeno-associated virus (aav) for enhanced gene therapy

Publications (1)

Publication Number Publication Date
IL297780A true IL297780A (en) 2022-12-01

Family

ID=76392408

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297780A IL297780A (en) 2020-05-01 2021-05-03 Controlled modification of adeno-associated virus (aav) for enhanced gene therapy

Country Status (9)

Country Link
US (1) US20230175013A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143206A1 (cg-RX-API-DMAC7.html)
JP (2) JP7862320B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005941A (cg-RX-API-DMAC7.html)
CN (1) CN115551878A (cg-RX-API-DMAC7.html)
AU (1) AU2021264081A1 (cg-RX-API-DMAC7.html)
CA (1) CA3177573A1 (cg-RX-API-DMAC7.html)
IL (1) IL297780A (cg-RX-API-DMAC7.html)
WO (1) WO2021222899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333058A (zh) * 2023-02-14 2023-06-27 国家纳米科学中心 可定点修饰抗原的病毒样颗粒及其构建方法与应用
WO2025188967A1 (en) 2024-03-06 2025-09-12 Trustees Of Boston College Precise adeno-associated virus-protein conjugates and uses thereof
TW202609054A (zh) * 2024-05-01 2026-03-01 日商Jcr製藥股份有限公司 經修飾之aav粒子、其製造方法、相關之醫藥及其製造方法
WO2026037731A1 (en) 2024-08-12 2026-02-19 Coave Therapeutics Squaramide-modified viral vectors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4480268B2 (ja) * 1998-02-12 2010-06-16 イミューン コンプレックス コーポレイション 戦略的修飾されたb型肝炎コアタンパク質及びそれらの誘導体
PL2657248T3 (pl) * 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) * 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
JP6836999B2 (ja) * 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
WO2019221992A1 (en) * 2018-05-15 2019-11-21 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties

Also Published As

Publication number Publication date
WO2021222899A1 (en) 2021-11-04
JP2026062759A (ja) 2026-04-10
EP4143206A1 (en) 2023-03-08
JP2023524401A (ja) 2023-06-12
US20230175013A1 (en) 2023-06-08
CN115551878A (zh) 2022-12-30
CA3177573A1 (en) 2021-11-04
KR20230005941A (ko) 2023-01-10
AU2021264081A1 (en) 2022-11-03
JP7862320B2 (ja) 2026-05-19

Similar Documents

Publication Publication Date Title
HUE062774T2 (hu) Módosított rAAV kapszidfehérje génterápiához
EP3856913A4 (en) Adeno-associated virus compositions for targeted gene therapy
PL3999119T3 (pl) Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
EP3575398A4 (en) ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
IL280636A (en) Alternative splicing regulation of gene expression and therapeutic methods
IL280637A (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
IL285238A (en) Gene therapy vectors for treatment of danon disease
CL2022000939A1 (es) Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c
IL299380A (en) An improved adenovirus as a vector for gene therapy
AU2019265855B2 (en) Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies
EP4013770A4 (en) AAV CAPSID VARIANTS FOR GENE THERAPY
EP3953484A4 (en) Aav-mediated gene therapy for maple syrup urine disease (msud)
IL287614A (en) Adeno-associated virus (aav) particles modified for gene therapy
EP4179098A4 (en) GENE THERAPY FOR STXBP1 ENCEPHALOPATHY
EP4048794A4 (en) Triple function adeno-associated virus (aav) vectors for the treatment of c9orf72 associated diseases
IL307604A (en) Adenoviral gene therapy vectors
EP3844294A4 (en) GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA
EP3802576A4 (en) FLOWMETER WITH FITTING WITH DRAIN TANK, TAP AND PLUG
DK3864053T3 (da) Behandling af rms ved at skifte terapi
IL285329A (en) Adeno-associated virus delivery of cln6 polynucleotide
EP4359519A4 (en) Adeno-associated viral (AAV) vectors for targeted tissue expression of therapeutic genes
EP4267200A4 (en) ADENOVIRAL VECTORS FOR GENE THERAPY
EP4743105A1 (en) VAA-BASED GENE THERAPY APPROACH FOR THE TREATMENT OF LGMD2B/DYSFERLINOPATHY
EP4106799A4 (en) ADENO-ASSOCIATED VIRAL (AAV)-MEDIATED SGPL1 GENE THERAPY FOR THE TREATMENT OF SPHINGOSINE-1-PHOSPHATE LYASE DEFICIENCY SYNDROME (SPLIS)
IL310017A (en) Retgc gene therapy